Australia's Monash IVF gets higher buyout offer, valuing it at $246 million

Washington H. Soul Pattinson and

13/04/2026 01:30

April 13 (Reuters) - Australia's Monash IVF MVF.AX said on Monday it had received a higher buyout offer from a consortium, valuing the fertility services provider at A$350.7 million ($246.19 million), sending its shares more than 20% higher in early trade.

Here are the details:

The consortium of private equity firm Genesis Capital Investment Management and Washington H. Soul Pattinson's SOL.AX investment arm increased the offer to A$0.90 per share from A$0.80 per share previously.

The new offer price represents a 35.3% premium to the stock's last closing price, higher than the previous proposal's 31.1% premium to the November 21 close.

Shares of Monash IVF were up more than 20% in early trade, hitting their highest level since December 23, 2025, and outperforming the Australian benchmark S&P/ASX 200 .AXJO, which was down 0.8%.

Monash IVF said the proposal was subject to exclusive due diligence that included a four-week period of exclusivity with no fiduciary exceptions.

Monash said its board was assessing the proposal, including obtaining advice from its financial and legal advisers.

Last year, the company rejected the previous offer from the consortium, saying the proposal was at a substantial discount to comparable IVF deals in the Australian market while highlighting uncertainty over the consortium's proposed financing arrangements.

The consortium had a 19.6% interest in the company, as of November 24, 2025.

The takeover offer was then withdrawn nearly a month later.

($1 = 1.4245 Australian dollars)

 (Reporting by Nichiket Sunil in Bengaluru; Editing by Subhranshu Sahu)

 ((Nichiket.Sunil@thomsonreuters.com;))